Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab conversion therapy for advanced gastric cancer with retroperitoneal metastasis
NCT05002686Phase 3Unknown
- Sponsor
- Ruijin Hospital
- Start
- Aug 2021
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in gastric cancer (GC), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05002686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05002686.